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Abstract Kinectin has been characterized as the first known
receptor for the molecular motor kinesin, which is critically
involved in microtubule-based vesicle transport and membrane
trafficking. Here we identify kinectin as a target for caspase-
mediated proteolysis during apoptosis. Treatment of cells with
diverse apoptotic stimuli including TNF, anti-Fas, anticancer
drugs, Q-radiation or ceramide leads to rapid proteolytic cleavage
of the 160-kDa form of kinectin to a 120-kDa fragment.
Evidence is provided that kinectin cleavage is mediated by
caspase 7.
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1. Introduction
Apoptosis, or programmed cell death, is a fundamental
process for normal development of multicellular organisms,
and is involved in the regulation of the immune system, nor-
mal morphogenesis, and maintenance of tissue homeostasis.
An important central mechanism in apoptotic cell death is
proteolytic cleavage of key cellular substrates by cysteine pro-
teases [1,2]. These proteases are related to mammalian inter-
leukin-1L converting enzyme (ICE) [3]. The caspase protease
family consists of at least 10 members which can be divided by
their phylogenic relationship and substrate speci¢city into
three subfamilies [4]. Those caspase members most closely
related to the cleavage during apoptosis are caspase 3, caspase
6 and caspase 7.
The identi¢ed substrates of caspase 3 include poly(ADP-
ribose) polymerase (PARP) [5,6], sterol-regulatory element-
binding proteins (SREBPs) [7,8], the U1-associated 70-kDa
protein [9], D4-GDI [10], huntingtin [11], the DNA-dependent
protein kinase [12,13], the DNA fragmentation factor (DFF)
[14], p21-activated kinase 2 (PAK2) [15], MEKK [16], gelsolin
[17] and retinoblastoma protein (RB) [18] to list a few.
It is not known whether the cleavage of any of these sub-
strates plays a causative role in apoptosis. Therefore, the iden-
ti¢cation and characterization of further physiological caspase
substrates appears mandatory to further our understanding of
the complex molecular and morphologic processes during
apoptotic cell death. The cellular signaling pathways involved
in controlling apoptosis remain poorly de¢ned as well. In
particular, little is known about the mechanisms underlying
the dramatic cytoskeletal, morphological, and membrane
changes that accompany cell death and that may be important
in the subsequent recognition and disposal of apoptotic cells
by phagocytic leukocytes.
Kinectin has been puri¢ed as a kinesin-binding protein of
160 kDa from the chick embryo brain [19]. A human homolog
has been cloned as a 4.6-kb mRNA species and characterized
as an integral membrane protein anchored in the endoplasmic
reticulum [20]. The properties of this protein suggested that
kinectin functions as a kinesin receptor that is required for
kinesin-dependent organelle movement [21]. Kinesin is a mem-
ber of an entire superfamily of ATP-driven motors in eukary-
otes (reviewed in [22]) which binds to and moves along a
microtubule substrate, powering a variety of transport proc-
esses, such as vesicle movement.
In this report we demonstrate that kinectin is cleaved by
caspase 7 during apoptosis induced by di¡erent stimuli. This
¢nding may be especially interesting because kinectin func-
tions as a membrane anchor for kinesin and may therefore
be relevant to the disruption of vesicle tra⁄cking during
apoptosis.
2. Material and methods
2.1. Cell culture and reagents
The human cervix carcinoma cell line HeLa, the human T-cell lym-
phoma cell lines Jurkat and HUT78 were obtained from the American
Type Culture Collection (ATCC, Rockville, USA). Cells were main-
tained in RPMI 1640 supplemented with 5% fetal calf serum, 2 mM
glutamine and 50 Wg/ml each of streptomycin and penicillin in a hu-
midi¢ed incubator containing 5% CO2.
Highly puri¢ed recombinant human TNF (hTNF, 3U107 U/mg
protein) was kindly provided by Dr. G. Adolf (Bender, Vienna, Aus-
tria). Anti-Fas antibody (IgM CH-11) was purchased from Coulter-
Immunotech. Monoclonal anti-PARP antibody was obtained from
Dr. G. Poirier (Quebec, Canada). Daunomycin, etoposide and cis-
platin were obtained from Sigma (Munich, Germany), protease inhib-
itors PMSF, Pefabloc and Complete from Boehringer Mannheim
(Germany) and DEVD-CHO and YVAD-CHO from Bachem (Hei-
delberg, Germany).
2.2. Preparation of cytosolic extracts from human cell lines
Cell extracts from Jurkat cells were prepared as described [23].
Brie£y, 2U108 cells were left untreated or treated with 100 WM etopo-
side for 3 h. Cells were washed twice with 50 ml PBS, followed by a
single wash with 5 ml cell extraction bu¡er (CEB; 50 mM PIPES, pH
7.4, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM dithiothreitol
(DTT), 10 WM cytochalasin B, 1 mM PMSF, 2 mM Pefabloc). Cells
were pelleted and after removal of supernatant, cells were transferred
to a Dounce homogenizer. After addition of one volume CEB (100 Wl/
108 cells), cells were incubated for 20 min on ice. Cells were lysed by
20^30 strokes in a homogenizer (Braun, Germany). Cell lysates were
transferred to 1.5-ml Eppendorf tubes and centrifuged at 4‡C for
20 min at 22 000Ug. The clear cytoplasmic lysate was transferred to
a new tube and diluted to 7.5 Wg/Wl protein using enzyme dilution
bu¡er (EDB: 10 mM HEPES, 50 mM NaCl, 2 mM MgCl2, 5 mM
EGTA, 1 mM DTT, 2 mM ATP, 10 mM phosphocreatine, 50 Wg/ml
creatine kinase). Extracts were used either immediately or stored at
380‡C. Western blot analyses were performed as described [24].
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2.3. In vitro cleavage of kinectin
The full-length cDNA of human kinectin was cloned into the EcoRI
site of Bluescript KS II (Stratagene). Cell-free reactions (total volume:
15 Wl) were performed with 1 Wl of in vitro transcribed/translated 35S-
labeled kinectin (TNT kit, Promega) and 1.5 Wl of recombinant casp-
ases 3, 6, 7 and 8 (Pharmingen) diluted in the assay bu¡er (20 mM
PIPES, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, 0.1% (w/v)
CHAPS and 10% sucrose, pH 7.2) [25]. The activity of caspases was
tested prior to the experiments in a £uorogenic assay measuring the
rate of Ac-DEVD-AFC hydrolysis in a Labsystems Fluoroskan 2, as
suggested by the company providing the caspases. The concentrations
of the caspases used were up to 130 nM for caspase 6, 5 nM and
16.5 nM for caspase 7, 82 nM for caspase 8 and 1.2 resp. 12 nM for
caspase 3. After incubation at 37‡C for one hour, samples were sub-
jected to SDS-PAGE and further analyzed using a Fuji BAS 1000
bioimager or exposure to a Kodak Biomax ¢lm.
2.4. Annexin-V-binding assay
Cells were washed with PBS, and resuspended in 100 Wl annexin-V-
FITC labeling solution (Boehringer Mannheim, Germany). After a
15-min incubation period, annexin-V-FITC staining was determined
by £ow cytometry analysis, using a £uorescence activated cell sorter
(Excalibur, Becton and Dickinson).
3. Results
3.1. Cleavage of kinectin is a general feature of apoptosis
HeLa or Jurkat cells were exposed to di¡erent apoptotic
stimuli, such as antitumor agents daunomycin and cis-platin,
TNF, ceramide or Q-radiation. As shown in Fig. 1 kinectin
degradation was observed in every instance, suggesting that
kinectin might serve as uniform target for proteases activated
in di¡erent cell types exposed to di¡erent stimuli. Degradation
of kinectin also occurs in primary leukemia cells treated with
etoposide or daunomycin (data not shown).
3.2. Degradation of kinectin during etoposide- and fas-induced
apoptosis
The fate of kinectin during apoptosis was analyzed by
Western blotting analysis. Treatment of the T-cell lymphoma
cell line HUT78 with anti-Fas monoclonal antibody (anti-Fas
mAb) over a period of 12 h resulted in a dose-dependent
conversion of kinectin from a 160-kDa form to a discrete
fragment with an approximate molecular weight of 120 kDa
(data not shown). Treatment of cells with 250 ng/ml anti-Fas
results in almost complete degradation of the 160-kDa form
of kinectin. A similar dose-dependent proteolytic degradation
of kinectin was also observed with the T cell-lymphoma cell
line Jurkat exposed for 12 h to the anticancer drug etoposide
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Fig. 1. Kinectin degradation is induced in di¡erent cell types by var-
ious apoptotic stimuli. HeLa or Jurkat cells were left untreated or
treated for 12 h with indicated concentrations of daunomycin (A)
or cis-platin (B). C: HeLa cells were left untreated or treated for 8 h
with recombinant human TNF. D: Jurkat cells were left untreated
or exposed to 25 Gy or 50 Gy Q-radiation and incubated for an ad-
ditional 12 h. Jurkat cells were also incubated for 12 h with 50 WM
of either C6- or C8-ceramide. Whole cell extracts were prepared and
analyzed by Western blotting. The arrows indicate the 160-kDa
(black arrow) and the 120-kDa (white arrow) forms of kinectin.
Fig. 2. Kinetics of kinectin cleavage during apoptosis. A: HUT78
cells were treated for the indicated times with 250 ng/ml anti-Fas
mAb. Cell lysates were prepared and analyzed by Western blotting
for the content of both kinectin and PARP. The percentage of
apoptotic cells was determined by £ow cytometry using annexin-V-
FITC. Jurkat cells (B) or HeLa cells (C) were left untreated or
treated for the indicated times with 200 WM etoposide or 100 ng/ml
TNF, and cellular extracts were analyzed for kinectin degradation.
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(data not shown). The extent of kinectin degradation corre-
sponds well with the degree of apoptosis, as measured by the
annexin-V-binding assay.
3.3. Kinetics of kinectin degradation
Proteolytic degradation of caspase targets such as PARP
has been observed as early as 2 h after induction of apoptosis
[12]. We have examined the time course of kinectin proteolysis
during cell death induced by Fas, etoposide or TNF. The 120-
kDa cleavage fragment of kinectin was discerned within 2^3 h
after treatment of HUT78 or HeLa cells with either anti-Fas
mAb or TNF, respectively (Fig. 2A,B), similar to the degra-
dation kinetics of the well de¢ned caspase substrate PARP
(Fig. 2A). The time course of kinectin degradation corre-
sponds well with annexin-V binding (Fig. 2A). These results
demonstrate that kinectin degradation is an early event in the
development of apoptosis. Notably, unlike Fas and TNF,
etoposide induced degradation of kinectin only after 6 h
(Fig. 2C). This delay of kinectin proteolysis, however, corre-
sponded well with the delayed time course of annexin-V bind-
ing (data not shown).
3.4. Degradation of kinectin is inhibited by caspase inhibitors
To examine the role of caspases in kinectin proteolysis we
employed YVAD-CMK, a speci¢c tetrapeptide inhibitor of
ICE (caspase 1) and DEVD-CHO, which preferentially inhib-
its caspase 3. Pretreatment of cells with YVAD did not inhibit
Fas-induced kinectin degradation and only partially blocked
etoposide at the highest concentrations used (200 WM) (data
not shown). In contrast, DEVD treatment leads to a dose-
dependent inhibition of both Fas- or etoposide-induced cleav-
age of kinectin with a close to complete inhibition at 200 WM
DEVD indicating the involvement of caspase 3-like proteases.
This distinct inhibitory activity of YVAD-CMK and DEVD-
CHO on Fas-induced kinectin degradation correlated with the
extent of inhibition of apoptosis (data not shown).
3.5. Degradation of kinectin in a cell-free system with
recombinant caspases
To investigate whether kinectin serves as a direct substrate
for caspases we employed a cell-free system, where in vitro
transcribed and translated kinectin was exposed to recombi-
nant caspases 3, 6, 7 and 8. As shown in Fig. 3A, proteolysis
of kinectin could be observed within 60 min when incubated
with caspase 7. The concentrations used and reaction condi-
tions had been described previously [25]. Even at higher con-
centrations other caspases showed no cleavage of kinectin.
The cleavage pattern seems to be identical when compared
to the results with intact cells (Figs. 1 and 2), suggesting
that proteolysis of kinectin occurs at a distinct cleavage site.
The in vitro translated kinectin shows amongst other, non-
speci¢c bands, one at a similar molecular weight as the cleav-
age product (120 kDa). This could be an alternatively spliced
variant as well.
4. Discussion
Although the precise biochemical pathways involved in the
execution of cell death during the apoptotic process are still
poorly understood it is now clear that proteases play an es-
sential role in the downstream processes resulting in the apop-
totic phenotype. However, a cause-relationship between the
proteolysis of these targets and the morphological and bio-
chemical alterations associated with apoptosis remain uncer-
tain.
Here we identify kinectin, the receptor for the molecular
motor protein kinesin as a substrate for proteolytic degrada-
tion during apoptosis. In TNF- or Fas-treated cells, degrada-
tion of kinectin could be detected within 2 h after induction of
apoptosis, at the same time when phosphatidylserine trans-
location became measurable. We could demonstrate with
long-term cultured cell lines and primary cells, that kinectin
is degraded speci¢cally and rapidly during the execution of
apoptosis induced by a number of di¡erent stimuli, such as
anti-Fas mAb, TNF, anticancer drugs, UV radiation and cer-
amide. These di¡erent stimuli probably use distinct molecular
pathways for the initiation phase of apoptosis, indicating that
kinectin may represent one point of convergence for di¡erent
pathways leading to apoptosis.
Treatment of intact cells with DEVD-CHO prevented Fas-
induced kinectin cleavage, whereas YVAD-CMK showed only
marginal inhibitory e¡ects. Because DEVD preferentially in-
hibits CPP32-like caspases these ¢ndings would suggest that a
caspase 3-like enzyme may be involved in the proteolytic
cleavage of kinectin. To further specify the caspase involved
in the cleavage of kinectin we tested in a cell free system the
degradation of kinectin with the recombinant caspases 3, 6, 7
and 8. Caspase 7 is the only caspase among these cleaving
kinectin with the same pattern shown previously in the cells
during apoptosis.
Caspase 7 was identi¢ed by the cloning of a cDNA detected
by PCR ampli¢cation of conserved caspase cDNA and called
MCH-3 [26]. It was also separately cloned from an EST and
called ICE-LAP3 (ICE-like apoptotic protease 3 [27] or
CMH1 (CPP32/Mch2 homolog 1) [28]. Overexpression of
caspase 7 induces apoptosis, and this protease is activated
during apoptosis induced by Fas, TNF or cytostatic agents.
Although caspases 3 and 7 have a closely related structure
[29] and almost identical tetrapeptide substrate speci¢city
FEBS 20857 25-9-98
Fig. 3. Speci¢c degradation of kinectin in a cell-free system by re-
combinant caspases. A: A full-length cDNA of human kinectin was
in vitro transcribed/translated (TNT-kit, Promega) using
[35S]methionine (NEN) for radioactive labeling. The 35S-labeled 160-
kDa translation product of kinectin is shown in lane 1. The in vitro
translated kinectin was incubated for indicated times with caspase 3,
6, 7 or 8 in the indicated concentration (lanes 2^6). Reaction prod-
ucts were analyzed by SDS-polyacrylamide gel electrophoresis fol-
lowed by autoradiography using a Fuji BAS1000 imager. The 160-
kDa (black arrow) and the 120-kDa (white arrow) forms of kinectin
are indicated.
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[30,31], kinectin is cleaved only by caspase 7 and not by casp-
ase 3 suggesting that caspase 7 may play a role distinct from
caspase 3. Detailed analysis of Fas-induced signaling using
novel synthetic tetrapeptides selectively inhibiting caspase 6
and caspase 3 provided evidence that the protease cascade
bifurcates into a caspase 7 arm and a caspase 3 arm each
inducing distinct downstream intracellular events [32]. Both
caspase 6 and 3 are supposed to play major roles in nuclear
apoptosis whereas caspase 7 is linked to cell shrinkage [32].
Further elucidation of cytoplasmic substrates speci¢c for casp-
ase 7 may clarify its role in the apoptotic process.
The molecular mechanism by which the caspases become
activated in the apoptotic process is currently not known.
The di¡erential sensitivity of Fas- and etoposide-induced kine-
ctin degradation might be explained by the di¡erent pathways
these stimuli use to induce apoptosis and to activate caspase 7.
The uniform cleavage of kinectin induced by diverse apop-
totic stimuli supports the idea that kinectin cleavage is an
important event in apoptosis. The ER membrane integral
160-kDa protein kinectin has been recently molecularly cloned
as the ¢rst kinesin receptor protein [33]. Kinesin is a member
of an entire superfamily of ATP-driven motors acting in the
microtubule-based motilities of organelles in eukaryotic cells.
More than 30 members of murine kinesin superfamily pro-
teins (KIFs) have been identi¢ed so far [34] whose detailed
identi¢cation of the cargo organelles is not yet fully under-
stood. It has been shown that microtubule-based motors play
an important role in membrane tra⁄cking pathways such as
ER formation, membrane recycling from transitional ER back
to ER or vesicle transport from the Golgi region to the plas-
ma membrane. Recent ¢ndings that anti-kinectin antibodies
can inhibit microtubule-based vesicle movement and kinesin
binding and its localization to the ER suggest that kinectin is
one essential membrane anchor used to connect vesicles to the
microtubule-based transport machinery [21]. It is conceivable
that the cleavage of kinectin will result in disruption of the
highly regulated membrane tra⁄cking pathways by discon-
necting the membrane vesicles from the microtubule-based
transport mechanisms.
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